CliffBio
biologic

Panhematin

Hemin for Injection

Loss of exclusivityJuly 1995projected — 12-year biologic exclusivity estimate
CompanyRecordati Rare Diseases Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand namePanhematin
Active ingredientHemin for Injection
Strength350MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJuly 1983
Marketing statusRx

More from Recordati Rare Diseases Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Panhematin patent cliff — loss of exclusivity July 1995 | CliffBio